Effects of smoking on the optimal effect-site concentration of remifentanil for preventing cough during anesthetic emergence in male patients undergoing laparoscopic or robotic cholecystectomy

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0003102

Enrollment

Registered

2018-08-20

Start date

2018-05-15

Completion date

Unknown

Last updated

2021-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Others : At the end of surgery, remifentanil Ce was titrated to a pre-determined concentration. This pre-determined Ce was maintained for at least 15 min throughout emergence. Immediately after extuba

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Male patients (20-65yrs) with American Society Anesthesiologist (ASA) physical status I or II undergoing laparoscopic cholecystectomy will be enrolled in this study

Exclusion criteria

Exclusion criteria: Patients with predicted difficult airway, body mass index > 30 kg/m2, history of upper respiratory infection or respiratory disease, current smokers, uncontrolled hypertension or diabetes, moderate to severe coronary artery disease wilil be excluded from the study.

Design outcomes

Primary

Measure	Time frame
EC50 and EC95 of remifentanil for preventing emergence cough	—

Secondary

Measure	Time frame
changes of blood pressure, HR;Respiratory complications including bradypnea(<8 /min), laryngospasm, and desaturation (SpO2 <95%);time to extubation;Concentration of sevoflurane at patient's eye opening (%);nausea, vomiting, and sedation score, and pain scores	—

Countries

Korea, Republic of

Contacts

Public ContactSook Young Lee

Ajou University

Outcome results